- Home
- AVPT vs RNA Comparison
AVPT vs RNA Comparison
Compare AVPT & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVPT
- RNA
- Stock Information
- Founded
- AVPT 2001
- RNA 2012
- Country
- AVPT United States
- RNA United States
- Employees
- AVPT N/A
- RNA N/A
- Industry
- AVPT Computer Software: Prepackaged Software
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- AVPT Technology
- RNA Health Care
- Exchange
- AVPT Nasdaq
- RNA Nasdaq
- Market Cap
- AVPT 3.0B
- RNA 3.4B
- IPO Year
- AVPT N/A
- RNA 2020
- Fundamental
- Price
- AVPT $18.85
- RNA $27.87
- Analyst Decision
- AVPT Buy
- RNA Strong Buy
- Analyst Count
- AVPT 5
- RNA 12
- Target Price
- AVPT $17.00
- RNA $68.25
- AVG Volume (30 Days)
- AVPT 877.0K
- RNA 1.4M
- Earning Date
- AVPT 05-08-2025
- RNA 05-08-2025
- Dividend Yield
- AVPT N/A
- RNA N/A
- EPS Growth
- AVPT N/A
- RNA N/A
- EPS
- AVPT N/A
- RNA N/A
- Revenue
- AVPT $349,012,000.00
- RNA $8,927,000.00
- Revenue This Year
- AVPT $18.61
- RNA N/A
- Revenue Next Year
- AVPT $18.52
- RNA $135.33
- P/E Ratio
- AVPT N/A
- RNA N/A
- Revenue Growth
- AVPT 21.70
- RNA N/A
- 52 Week Low
- AVPT $8.06
- RNA $21.51
- 52 Week High
- AVPT $19.90
- RNA $56.00
- Technical
- Relative Strength Index (RSI)
- AVPT 77.79
- RNA 45.31
- Support Level
- AVPT $16.56
- RNA $25.58
- Resistance Level
- AVPT $17.30
- RNA $33.62
- Average True Range (ATR)
- AVPT 0.49
- RNA 2.09
- MACD
- AVPT 0.29
- RNA -0.29
- Stochastic Oscillator
- AVPT 84.40
- RNA 28.53
About AVPT AvePoint Inc.
AvePoint Inc provides customizable solutions to optimize SaaS operations, enable secure collaboration, and accelerate digital transformation across technologies and industries. Its Confidence Platform delivers a comprehensive set of cloud-based solutions enabling IT operations, development operations, and cybersecurity professionals to monitor and secure the digital workplace using SaaS tools.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.